PPD

OCTOBER 18, 2023

Continued expansion of the biotech industry is occurring in parallel, with an estimated compound annual growth rate of 13.96% from 2023-2030. There has been an unprecedented expansion of different types of pharmaceutical therapies, as well as a change in the overall approach to health care.

Laboratories 52

Laboratories Assay Development Small Molecule Drug Development 52

The Pharma Data

SEPTEMBER 10, 2021

Haystack will receive a prize package that includes investment from SVG Ventures and a place in THRIVE’s award winning Accelerator Program, in addition to access to Bayer’s investment and R&D teams. MagGrow is the winner of the Sustainable Scaleup Award.

Packaging 52

Packaging Science Marketing Production 52

The Pharma Data

OCTOBER 29, 2020

These immense benefits can be achieved through investment in five proven and cost-effective intervention packages recommended by WHO to address the major NCD risk factors. . Scaling up efforts on the prevention and control of non-communicable diseases (NCDs) can avert over 4.3 million deaths and yield RUB 8.1

Disease 40

Disease Packaging Government Production 40

Agency IQ

NOVEMBER 20, 2023

readability of package leaflet, patient engagement). Summary of Product Characteristics and Package Leaflet), recommending that sponsors and regulators “explore the use of electronic media” to provide product information “in the future”. The report recognized the potential for an electronic format for Product Information (i.e.,

Production 40

Production Packaging Hospitals Regulations 40

Agency IQ

MARCH 15, 2024

Background: SB 54 and its requirements On June 30, 2022, Governor Gavin Newsom signed into effect SB 54, the Plastic Pollution Prevention and Packaging Producer Responsibility Act. Cutting waste: By 2032, SB 54 requires that the state cut the use of single-use packaging and food service ware by 25%.

Regulations 40

Regulations Packaging Compliance Production 40

Agency IQ

FEBRUARY 23, 2024

NANCY SKINNER has updated a bill she introduced in early January 2024 to ban the sale of intentionally added PFAS in the state after 2030. In early January 2020, DTSC also held a workshop on PFAS in food packaging , including panel discussions and presentations on potential alternatives.

Packaging 40

Packaging Regulations Production Compliance 40

Agency IQ

MAY 10, 2024

In general, the law also pushes out a prohibition on almost all products with intentionally added PFAS from January 2030 to January 2032 , except for some cooling, heating, and refrigerant products which will be allowed until 2040.

Packaging 40

Packaging Regulations Production Compliance 40

Vial

FEBRUARY 23, 2024

billion and is expected to climb at a compound annual growth rate (CAGR) of 19.44% between 2023 and 2030. The HITECH Act invested $19 billion into health information technology, such as EMRs and digital patient portals, to serve as an economic stimulus package and incentivize their adoption by healthcare providers.

Clinical Trials 52

Clinical Trials Clinical Research Trials Hospitals 52

Codon

MARCH 24, 2024

In the case of semaglutide, those cells are Saccharomyces cerevisiae— also known as Baker’s yeast — engineered to secrete a peptide precursor that is later purified, chemically modified, packaged into an injectable or tablet form, and then shipped around the world. Continuing this method may not scale.

Engineering 84

Engineering Vaccine Production RNA 84

Agency IQ

JUNE 28, 2024

In 2030, the law will ban the use of any product with intentionally added PFAS, unless the Maine legislature determines that the product currently serves an unavoidable use. In addition, the law prohibits the sale of carpets or fabric treatments containing PFAS as of January 1, 2023.

Production 40

Production Regulations Compliance Packaging 40

The Pharma Data

JANUARY 9, 2021

CDMO Services assumes continued growth in Development Services (DVS), Drug Substance (DS) manufacturing, and Drug Product (DP) manufacturing and Packaging for both clinical- and commercial-stage projects on behalf of a growing list of pharmaceutical and biotechnology innovators and government/NGO customers. FOOTNOTES. (1)

Government 40

Government Vaccine Production Licensing 40

The Pharma Data

NOVEMBER 5, 2020

In August 2020 , the Company issued and sold $1.250 billion aggregate principal amount of 1.750% senior unsecured notes due 2030 and $750 million aggregate principal amount of 2.800% senior unsecured notes due 2050. A reconciliation of the Company’s GAAP to non-GAAP results is included in Table 3 of this press release.

Production 40

Production FDA Trials FDA Approval 40

The Pharma Data

OCTOBER 18, 2020

Mitigating the impact of COVID-19 on essential HIV, hepatitis and STI services; Proposing key elements, themes and principles for 2022-2030 strategies; Balancing the need for disease specificity and sustainability in health including through universal health coverage, primary healthcare and health systems strengthening; and. Other issues.

Packaging 52

Packaging Disease Science Drugs 52

Agency IQ

DECEMBER 1, 2023

This package would propose updates to the alternative work practice as appropriate based on the review and address the issues raised for reconsideration. The standards would begin with model year 2027 heavy-duty vehicles, with stringency levels through model year 2030 and beyond.

Regulations 40

Regulations Production Science Compliance 40

Agency IQ

DECEMBER 15, 2023

For this routine MUR, EPA will only consider new methods or method revisions for which a complete, acceptable method package has been received by January 7, 2022. Monitoring preparations are anticipated in 2027, with sample collection between 2028-2030 and reporting concluding in 2031.

Regulations 40

Regulations Compliance Production Government 40

Agency IQ

JUNE 16, 2023

This package would propose updates to the alternative work practice as appropriate based on the review and address the issues raised for reconsideration. The standards would begin with model year 2027 heavy-duty vehicles, with stringency levels through model year 2030 and beyond.

Regulations 40

Regulations Compliance Production Science 40

Codon

OCTOBER 27, 2024

In 2014, the World Health Organization (WHO) proposed an initiative called the End TB Strategy , aimed at reducing cases by 80 percent, deaths by 90 percent, and diagnostic/treatment costs by 100 percent by 2030. Regrettably, the initiative is not on track to meet any of those targets.

Immune Response 81

Immune Response Doctors Disease Laboratories 81